Company · Biotechnology Research
Poltreg S.A
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.
Team composition
Roles at Poltreg S.A
51 to 200 staff
- 5poltreg s a
- 2biotechnologist
- 1board member
- 1clinical trial drirector
- 1clinical trial specialist
- 1kierownik działu projektów i compliance
- 1medical director dyrektor medyczny
- 1production biotechnologist
- 1project leader
- 1prokurent
- +3more roles
On record
Showing 9 of 18
Reveal on Kipplo
Get the full team — names, verified emails, phone numbers — in the Kipplo app.
Unlock teamFiled under Biotechnology Research in Poland.